III期非小细胞肺癌选择性淋巴结照射在IMRT下是否仍安全:前瞻性队列研究结果
该前瞻性队列研究纳入2010年1月至2012年3月接受根治性IMRT的183例III期NSCLC患者,中位随访58.0个月,孤立性淋巴结失败(INF)率为2.2%,中位PFS 15.0个月、中位OS 19.5个月,提示IMRT下选择性淋巴结照射的野内INF发生率低,与3D-CRT相似,可考虑为安全。
要点
- III期NSCLC接受IMRT选择性淋巴结照射,中位随访58.0个月INF率仅2.2%。
- 中位PFS 15.0个月,中位OS 19.5个月,急性毒性有限。
- 1例INF为野邻近淋巴结,支持IMRT下选择性淋巴结照射安全性。
核心结论
- III期NSCLC患者使用IMRT行选择性淋巴结照射,野内INF发生率为2.2%,与3D-CRT相似,可认为安全。
研究设计与样本
- 前瞻性队列研究,纳入2010年1月至2012年3月接受根治性IMRT的III期NSCLC患者183例。
- 主要终点为INF发生率,次要终点包括失败模式、PFS、OS和毒性。
主要发现
- 中位随访58.0个月,2.2%的患者发生INF。
- 中位PFS为15.0个月,中位OS为19.5个月。
- 复发模式:INF 2.2%,局部复发11.5%,局部区域复发2.7%,仅远处转移26.8%,局部/局部区域合并远处转移18.0%,无复发38.3%。
- 1例INF为野邻近淋巴结。
- 急性毒性有限。
临床怎么用
- III期NSCLC根治性IMRT可采用选择性淋巴结照射,野内INF风险低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Isolated nodal failures (INF) are rare after 3D-conformal radiotherapy (3D-CRT) for stage III non-small cell lung cancer (NSCLC). Since incidental nodal irradiation doses are lower with Intensity Modulated Radiation Therapy (IMRT) than with 3D-CRT, INF may be higher after IMRT. We therefore investigated the incidence of INF after IMRT in stage III NSCLC patients. MATERIALS AND METHODS: Stage III NSCLC patients undergoing radical radiotherapy using IMRT in the period January 2010 till March 2012 were included. The primary endpoint was the rate of INF, secondary endpoints included patterns of failure, progression free survival (PFS), overall survival (OS) and toxicity. RESULTS: 183 stage III NSCLC patients were enrolled. With a median follow-up of 58.0months 2.2% of patients had an INF. The median PFS was 15.0months, the median OS 19.5months. Patterns of recurrence: 2.2% INF, 11.5% local and 2.7% loco-regional recurrence, 26.8% distant metastases only, 18.0% a combination of local/loco-regional and distant metastases, and 38.3% patients without recurrence. One INF was out of field, in adjacent lymph nodes. Acute toxicity was limited. DISCUSSION: Selective nodal irradiation using IMRT in stage III NSCLC patients results in a low in-field incidence of INF (2.2%), similar to 3D-CRT, and may thus be considered safe.
引用
- Martinussen HM, Reymen B, Wanders R, et al. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. Radiother Oncol. 2016. PMID: 27884510. doi:10.1016/j.radonc.2016.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。